PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
3.82
Similar to CRVO's ratio of 3.59. Walter Schloss would see both operating with a similar safety margin.
3.82
Similar ratio to CRVO's 3.59. Walter Schloss might see both running close to industry norms.
3.73
Cash Ratio 1.25–1.5x CRVO's 3.31. Bruce Berkowitz might see a strong liquidity buffer compared to the competitor.
-958.91
Negative interest coverage while CRVO shows 0.00. Joel Greenblatt would look for earnings improvements and debt restructuring catalysts.
No Data
No Data available this quarter, please select a different quarter.
